Forbes October 23, 2024
In 2016, the Belgian cancer biologist Eleonora Leucci published the first of several papers on a particular RNA molecule named SAMMSON which was notably active in melanoma tumors.
Over the past eight years, Leucci and others have repeatedly shown SAMMSON to be crucial for the survival of melanoma cells, making it one of the most compelling new drug targets for the treatment of both primary and metastatic melanomas. For the Australian molecular biologist John Mattick, who has spent much of his career attempting to assign function to pieces of the genome once described as ‘junk’, SAMSSON represents how so-called long non-coding RNAs – commonly abbreviated to lncRNAs – can be used as novel drug targets for a whole range of...
Today's Sponsors
Today's Sponsor